Form 4 for KPRX KIORA PHARMACEUTICALS INC
Accepted 2025-04-02 00:00:00 ET · period of report 2025-04-01 · accession 0001372514-25-000036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-02 | 2025-04-01 | KPRX | Tosca Melissa | CFO | A - Grant | $0.00 | +7,772 | 21.4K | +57% | $0 |
| D | 2025-04-02 | 2025-04-01 | KPRX | Tosca Melissa | CFO | A - Grant | $0.00 | +15.5K | 15.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-01 | A | A | 7,772 | $0.00 | 21,371 | D | — | — | (F1) Grant of restricted stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of April 1, 2026, April 1, 2027 and April 1, 2028, subject to the reporting person's continuous service through each such vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-04-01 | A | A | 15,543 | $0.00 | 15,543 | D | $2.93 · 2026-04-01 to 2035-04-01 | 15,543 Common Stock | (F2) The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on April 1, 2026, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date. |